An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome.

European Heart Journal — Cardiovascular Pharmacotherapy Pub Date : 2020-04-01 DOI:10.1093/ehjcvp/pvz079

Heinz Drexel, Andrew J S Coats, Ilaria Spoletini, Claudio Bilato, Vincenzo Mollace, Pasquale Perrone Filardi, Giuseppe M C Rosano

{"title":"An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome.","authors":"Heinz Drexel, Andrew J S Coats, Ilaria Spoletini, Claudio Bilato, Vincenzo Mollace, Pasquale Perrone Filardi, Giuseppe M C Rosano","doi":"10.1093/ehjcvp/pvz079","DOIUrl":null,"url":null,"abstract":"<p><p>Benefits and safety on statins have been well-established over 20 years of research. Despite this, the vast majority of patients are not adequately treated and do not achieve the low-density lipoprotein cholesterol target levels. This is mainly due to poor adherence, which is associated with dangerous and sometimes fatal outcomes. To increase adherence and prevent worse outcomes, a combination therapy with lower dosage of statins and new lipid-lowering drugs may be used. However, the implementation of new lipid-lowering drugs in European countries is still at the beginning. For these reasons, the aim of this position paper is to give an up-to-date indication from the ESC Working Group on Cardiovascular Pharmacotherapy in order to discuss the barriers towards statins adherence and new lipid-lowering drugs implementation in Europe.</p>","PeriodicalId":11995,"journal":{"name":"European Heart Journal — Cardiovascular Pharmacotherapy","volume":" ","pages":"115-121"},"PeriodicalIF":0.0000,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/ehjcvp/pvz079","citationCount":"37","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Heart Journal — Cardiovascular Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ehjcvp/pvz079","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 37

Abstract

Benefits and safety on statins have been well-established over 20 years of research. Despite this, the vast majority of patients are not adequately treated and do not achieve the low-density lipoprotein cholesterol target levels. This is mainly due to poor adherence, which is associated with dangerous and sometimes fatal outcomes. To increase adherence and prevent worse outcomes, a combination therapy with lower dosage of statins and new lipid-lowering drugs may be used. However, the implementation of new lipid-lowering drugs in European countries is still at the beginning. For these reasons, the aim of this position paper is to give an up-to-date indication from the ESC Working Group on Cardiovascular Pharmacotherapy in order to discuss the barriers towards statins adherence and new lipid-lowering drugs implementation in Europe.

查看原文本刊更多论文

ESC心血管药物治疗工作组关于他汀类药物依从性和新型降脂药物实施的专家意见论文:需要克服的障碍。

他汀类药物的益处和安全性已经在20多年的研究中得到了证实。尽管如此，绝大多数患者没有得到充分的治疗，没有达到低密度脂蛋白胆固醇的目标水平。这主要是由于依从性差，这与危险，有时甚至是致命的结果有关。为了增加依从性和防止更坏的结果，可以使用低剂量的他汀类药物和新的降脂药物的联合治疗。然而，新的降脂药物在欧洲国家的实施仍处于起步阶段。出于这些原因，本立场文件的目的是给出ESC心血管药物治疗工作组的最新适应症，以讨论他汀类药物依从性和新降脂药物在欧洲实施的障碍。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Heart Journal — Cardiovascular Pharmacotherapy

自引率

0.00%

发文量